WO1999059615A1 - Hybrid polypeptides with enhanced pharmacokinetic properties - Google Patents
Hybrid polypeptides with enhanced pharmacokinetic properties Download PDFInfo
- Publication number
- WO1999059615A1 WO1999059615A1 PCT/US1999/011219 US9911219W WO9959615A1 WO 1999059615 A1 WO1999059615 A1 WO 1999059615A1 US 9911219 W US9911219 W US 9911219W WO 9959615 A1 WO9959615 A1 WO 9959615A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptide
- core
- hybrid
- core polypeptide
- enhancer peptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked.
- the invention is based, in part, on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life.
- the invention further relates to novel anti-fusogenic and/or anti-viral, peptides, including ones that contain such enhancer peptide sequences, and methods for using such peptides.
- the invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide.
- the core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.
- the invention is demonstrated by way of example wherein a hybrid polypeptide comprising, for example, an HIV core polypeptide linked to enhancer peptide sequences, is shown to be a potent, non-cytotoxic inhibitor of HIV-1, HIV-2 and SIV infection.
- the enhancer peptide sequences of the invention have been linked to a respiratory syncytial virus (RSV) core polypeptide and a luteinizing hormone receptor (LH-RH) core polypeptide.
- RSV respiratory syncytial virus
- LH-RH luteinizing hormone receptor
- the hybrid polypeptide was found to possess enhanced pharmacokinetic properties, and the RSV hybrid polypeptide exhibited substantial anti-RSV activity.
- Polypeptide products have a wide range of uses as therapeutic and/or prophylactic reagents for prevention and treatment of disease. Many polypeptides are able to regulate biochemical or physiological processes to either prevent disease or provide relief from symptoms associated with disease. For example, polypeptides such as viral or bacterial polypeptides have been utilized successfully as vaccines for prevention of pathological diseases. Additionally, peptides have been successfully utilized as therapeutic agents for treatment of disease symptoms. Such peptides fall into diverse categories such, for example, as hormones, enzymes, immunomodulators, serum proteins and cytokines.
- polypeptides For polypeptides to manifest their proper biological and therapeutic effect on the target sites, the polypeptides must be present in appropriate concentrations at the sites of action. In addition, their structural integrity must generally be maintained. Therefore, the formulation of polypeptides as drugs for therapeutic use is directed by the chemical nature and the characteristics of the polypeptides, such as their size and complexity, their conformational requirements, and their often complicated stability, and solubility profiles. The pharmacokinetics of any particular therapeutic peptide is dependent on the bioavailability, distribution and clearance of said peptide.
- the present invention relates, first, to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences i.e. , HIV-1, HIV-2 and SIV, that enhance the pharmacokinetic properties of any core polypeptide to which they are linked.
- the invention is based on the surprising result that when the disclosed enhancer peptide sequences are linked to any core polypeptide, the resulting hybrid polypeptide possesses enhanced pharmacokinetic properties including, for example, increased half life and reduced clearance rate relative to the core polypeptide alone.
- the present invention further relates to such hybrid polypeptides and core polypeptides, and to novel peptides that exhibit anti-fusogenic activity, antiviral activity and/or the ability to modulate intracellular processes that involve coiled-coil peptide structures.
- novel peptides that exhibit anti-fusogenic activity, antiviral activity and/or the ability to modulate intracellular processes that involve coiled-coil peptide structures.
- Such peptides are ones that contain enhancer peptide sequences .
- Core polypeptides can comprise any peptides which may be introduced into a living system, for example, any peptides capable of functioning as therapeutic, prophylactic or imaging reagents useful for treatment or prevention of disease or for diagnostic or prognostic methods, including methods in vivo imaging.
- Such peptides include, for example, growth factors, hormones, cytokines, angiogenic growth factors, extracellular matrix polypeptides, receptor ligands, agonists, antagonists or inverse agonists, peptide targeting agents, such as imaging agents or cytotoxic targeting agents, or polypeptides that exhibit antifusogenic and/or antiviral activity, and peptides or polypeptides that function as antigens or immunogens including, for example, viral and bacterial polypeptides.
- the invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the core polypeptide to the enhancer peptide sequences to form hybrid polypeptides.
- the invention still further relates to methods for using the peptides disclosed herein, including hybrid polypeptides containing enhancer peptide sequences.
- the methods of the invention include methods for decreasing or inhibiting viral infection, e.g. , HIV-1, HIV-2, RSV, measles, influenza, parainfluenza, Epstein-Barr, and hepatitis virus infection, and/or viral-induced cell fusion events.
- the enhancer peptide sequences of the invention can, additionally, be utilized to increase the in vitro or ex-vivo half-life of a core polypeptide to which enhancer peptide sequences have been attached, for example, enhancer peptide sequences can increase the half life of attached core polypeptides in cell culture or cell or tissue samples.
- hybrid polypeptides containing an HIV core polypeptide linked to enhancer peptide sequences are shown to exhibit greatly enhanced pharmacokinetic properties and act as a potent, non- cytotoxic inhibitors of HIV-1, HIV-2 and SIV infection.
- hybrid polypeptides containing an RSV core polypeptide or a luteinizing hormone polypeptide are shown to exhibit greatly enhanced pharmacokinetic properties.
- the RSV hybrid polypeptide exhibited substantial anti-RSV activity.
- Peptides, polypeptides and proteins are defined herein as organic compounds comprising two or more amino acids covalently joined, e.g. , by peptide amide linages. Peptides, polypeptide and proteins may also include non-natural amino acids and any of the modifications and additional amino and carboxyl groups as are described herein. The terms "peptide,” “polypeptide” and “protein” are, therefore, utilized interchangeably herein. Peptide sequences defined herein are represented by one- letter symbols for amino acid residues as follows: A f alanine)
- Enhancer peptide sequences are defined as peptides having the following consensus amino acid sequences: "WXXWXXI” , “ XXWXX”, “ XXWXX”, “ XXWX”, “WXXW”, “WXXWXWX”, “XXXWXWX”, “XXWXWX”, “XWXWX”, “XWXWX”, “XWXWX”, “XWXWX”, “WXXWXW”, “WXXWXW”, “XXXW”, "IXXXWXW”, "XXWXW”, “XWXW”, “XWXWXW”, “XWXWXXW”, “XWXWXXX”, “XWXWXXX”, “XWXWXX” , “XWXWXX”, “XWXWXX” , “XWXWXX”, “XWXWXX” , “XWXWX”, “XWX
- the enhancer peptide sequences of the invention also include peptide sequences that are otherwise the same as the consensus amino acid sequences but contain amino acid substitutions, insertions or deletions but which do not abolish the ability of the peptide to enhance the pharmacokinetic properties of a core peptide to which it is linked relative to the pharmacokinetic properties of the core polypeptide alone.
- Core polypeptide refers to any polypeptide which may be introduced into a living system and, thus, represents a bioactive molecule, for example any polypeptide that can function as a pharmacologically useful peptide for treatment or prevention of disease.
- Hybrid polypeptide refers to any polypeptide comprising an amino, carboxy, or amino and carboxy terminal enhancer peptide sequence and a core polypeptide. Typically, an enhancer peptide sequence is linked directly to a core polypeptide. It is to be understood that an enhancer peptide can also be attached to an intervening amino acid sequence present between the enhancer peptide sequence and the core peptide.
- Antifusogenic and anti-membrane fusion refer to a peptide *s ability to inhibit or reduce the level of fusion events between two or more structures e.q. , cell membranes or viral envelopes or pili, relative to the level of membrane fusion which occurs between the structures in the absence of the peptide.
- Antiviral refers to the peptide* s ability to inhibit viral infection of cells via, e.q. , cell fusion or free virus infection. Such infection can involve membrane fusion, as occurs in the case of enveloped viruses, or another fusion event involving a viral structure and a cellular structure, e.q. , fusion of a viral pilus and bacterial membrane during bacterial conjugation) .
- FIG. 1 Hybrid polypeptides. Enhancer peptide sequences derived from putative N-terminal and C-terminal interactive regions are depicted linked to a generic core polypeptide. Conserved enhancer peptide sequences are shaded. It is to be noted that the enhancer peptide sequences indicated may be used either as - terminal, C- terminal, or - and C-terminal additions. Further, the enhancer peptide sequences can be added to a core polypeptide in forward or reverse orientation, individually or in any of the possible combinations, to enhance pharmacokinetic properties of the peptide.
- FIG. 2A Enhancer peptide sequences derived from various envelope (gp41) protein sequences, representing the N-terminal interactive region observed in all currently published isolate sequences of HIV-1, HIV-2 and SIV.
- the final sequence "WXXWXXI" represents a consensus sequence.
- FIG. 2B Enhancer peptide sequence variants derived from various envelope (gp41) protein sequences, representing the C-terminal interactive region observed in all currently published isolate sequences of HIV-1, HIV-2 and SIV.
- the final sequence "WXXXWXWX” represents a consensus sequence.
- FIG. 3 Comparison of HIV-1 titres in tissues of HIV-1 9320 infected SCID-HuPBMC mice as measured by P24 Levels in HuPBMC co-culture assays. The figure shows a comparison of in vivo T20 and T1249 viral inhibition.
- FIG. 4A-4B Plasma pharmacokinetic profile of T1249 vs. T1387 core control in CD-rats following IV injection for up to 2 hrs (FIG. 4A) and 8 hrs (FIG. 4B) .
- the T1387 polypeptide is a core polypeptide and the T1249 polypeptide is the core polypeptide linked to enhancer peptide sequences.
- FIG. 5 Plasma pharmacokinetic profile of T1249 vs. T20 control in CD-rats following IV administration.
- the T1249 polypeptide is a hybrid polypeptide of a core polypeptide (T1387) linked to enhancer peptide sequences.
- FIG. 6 Comparison of T20/T1249 Anti-HIV-1/IIIb activity and cytotoxicity.
- FIG. 7 Direct Binding of T1249 to gp41 construct
- FIG. 8 Time Course of T1249 Association/Dissociation. The results demonstrate that 125 I-T1249 and 15 I-T20 have similar binding affinities of 1-2 nM. Initial on and off rates for 125 I-T1249 were significantly slower than those of 125I-T20. Dissociation of bound radioligand was measured following the addition of unlabeled peptide to a final concentration of lO ⁇ m in 1/10 total assay volume.
- FIG. 9 Competition for T1249 Binding to M41 ⁇ 178. Unlabeled T1249 and T20 were titrated in the presence of a single concentration of either 125 I-T1249 or 125 I-T20. Ligand was added just after the unlabeled peptide to start the incubation.
- FIG. 10A-10B Plasma pharmacokinetic profile of RSV hybrid polypeptides T1301 (10A) and T1302 (10B) vs. T786 in
- FIG. 11A Plaque Reduction Assay.
- Hybrid polypeptide T1293 is capable of inhibiting RSV infection with an IC 50 2.6 ⁇ g/ml.
- FIG. 11B Plaque Reduction Assay demonstrates the ability of RSV Hybrid Polypeptides T1301, T1302 and T1303 to inhibit RSV infection.
- FIG. 12A and 12B Plasma pharmacokinetic profile of luteinizing hormone hybrid polypeptide T1324 vs T1323 in CD male rats.
- the T1323 polypeptide is a luteinizing hormone core polypeptide and the T1324 polypeptide is a hybrid polypeptide comprising a core polypeptide linked to enhancer peptide sequences.
- FIG. 13 Hybrid polypeptide sequences derived from various core polypeptides. Core polypeptide sequences are shown shaded. The non-shaded amino and carboxy terminal sequences represent enhancer peptide sequences.
- FIG. 14A-B Circular Dichroism (CD) spectra for T1249 in solution (phosphate buffered saline, pH 7) alone (10 ⁇ M at 12C; FIG. 14A) and in combination with a 45-residue peptide from the gp41 HR1 binding domain (T1346) ; the closed square ( ⁇ ) represents a theoretical CD spectrum predicted for a "non-interaction model" whereas the actual CD spectra are represented by the closed circle (•) .
- CD Circular Dichroism
- FIG. 15 Polyacrylamide gel electrophoresis showing T1249 protection of the gp41 construct M41 ⁇ 178 from proteinase-K digestion; lane 1: primer marker; lane 2: untreated M41 ⁇ 178; lane 3: M41 ⁇ 178 incubated with proteinase-K; lane 4: untreated T1249; lane 5: T1249 incubated with proteinase-K; lane 6: M41 ⁇ 178 incubated with T1249; lane 7: incubation of T1249 and M41 ⁇ 178 prior to addition of proteinase-K.
- FIG. 16A-C Pharmacokinetics of T1249 in Sprague-Dawley albino rats; FIG. 16A: pharmacokinetics of T1249 in a single dose administration by continuous subcutaneous infusion; FIG. 16B: Plasma pharmacokinetics of T1249 administered by subcutaneous injection (SC) or intravenous injection IV) ; FIG. 16C: Kinetic analysis of T1249 in lymph and plasma after intravenous administration.
- SC subcutaneous injection
- IV intravenous injection IV
- FIG. 17A-B Pharmacokinetics of T1249 in cynomolgus monkeys
- FIG. 17A plasma pharmacokinetics of a single 0.8 mg/kg dose of T1249 via subcutaneous (SC) intravenous (IV) or intramuscular (IM) injection
- FIG. 17B Plasma pharmacokinetics of subcutaneously administered T1249 at three different dose levels (0.4 mg/kg, 0.8 mg/kg, and 1.6 mg/kg) .
- enhancer peptide sequences derived from various retroviral envelope (gp41) protein sequences that are capable of enhancing the pharmacokinetic properties of core polypeptides to which they are linked.
- enhancer peptide sequences can be utilized in methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide to form a hybrid polypeptide with enhanced pharmacokinetic properties relative to the core polypeptide alone.
- the half life of a core peptide to which an enhancer peptide sequence or sequences has been attached can also be increased in vitro.
- attached enhancer peptide sequences can increase the half life of a core polypeptide when present in cell culture, tissue culture or patient samples, such as cell, tissue, or other samples.
- the core polypeptides of the hybrid polypeptides of the invention comprise any peptide which may be introduced into a living system, for example, any peptide that can function as a therapeutic or prophylactic reagent useful for treatment or prevention of disease, or an imaging agent useful for imaging structures in vivo.
- peptides including peptides that contain enhancer peptide sequences, that exhibit anti- fusogenic and/or anti-viral activity. Further described herein are methods for utilizing such peptides, including methods for decreasing or inhibiting viral infection and/or viral induced cell fusion.
- the hybrid polypeptides of the invention comprise at least one enhancer peptide sequence and a core polypeptide.
- the hybrid polypeptides of the invention comprise at least two enhancer peptide sequences and a core polypeptide, with at least one enhancer peptide present in the hybrid polypeptide amino to the core polypeptide and at least one enhancer peptide sequence present in the hybrid polypeptide carboxy to the core polypeptide.
- the enhancer peptide sequences of the invention comprise peptide sequences originally derived from various retroviral envelope (gp 41) protein sequences, including HIV-1, HIV-2 and SIV sequences, and specific variations or modifications thereof described below.
- a core polypeptide can comprise any peptide sequence, preferably any peptide sequence that may be introduced into a living system, including, for example, peptides to be utilized for therapeutic, prophylactic or imaging purposes.
- a hybrid polypeptide will range in length from about 10 to about 500 amino acid residues, with about 10 to about 100 amino acid residues in length being preferred, and about 10 to about 40 amino acids in length being most preferred.
- the structure of the envelope protein is such that the putative -helix region located in the C-terminal region of the protein is believed to associate with the leucine zipper region located in the N-terminal region of the protein. Alignment of the N-terminal and C-terminal enhancer peptide sequence gp41 regions observed in all currently published isolate sequences of HIV-1, HIV-2 and SIV identified consensus amino acid sequences.
- an enhancer peptide sequence will be about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 amino acid residues in length, with about 4 to about 20 residues in length being preferred, about 4 to about 10 residues in length being more preferred, and about 6 to about 8 residues in length being most preferred.
- enhancer peptide sequences which may be used to enhance the pharmacokinetic properties of the resultant hybrid polypeptides comprise the specific enhancer peptide sequences depicted in FIGS. 2, 13, and Table 1, below. /Among the most preferred enhancer peptide sequences are ones comprising the following amino sequence: "WQEWEQKI” and "WASLWEWF” .
- Table 1 lists amino acid sequences that represent preferred embodiments of the enhancer peptide sequences of the enhancer peptide sequences of the invention. It is to be understood that while the forward orientation of these sequences is depicted below, the reverse orientation of the sequences is also intended to fall within the scope of the present invention. For example, while the forward orientation of the enhancer peptide sequence "WMEWDREI” is depicted below, its reverse orientation, i.e. , "IERDWEMW" is also intended to be included.
- particular enhancer peptide sequences of the invention comprise the enhancer peptide sequences depicted in FIGS. 2, 13 and Table 1 exhibiting conservative amino acid substitutions at one, two or three positions, wherein said substitutions do not abolish the ability of the enhancer peptide sequence to enhance the pharmacokinetic properties of a hybrid polypeptide relative to its corresponding core polypeptide.
- substitutions result in enhancer peptide sequences that fall within one of the enhancer peptide sequence consensus sequences.
- the substitutions are made at amino acid residues corresponding to the "X" positions depicted in the consensus amino acid sequences depicted above and in FIGS. 1 and 2.
- Constant substitutions refer to substitutions with amino acid residues of similar charge, size and/or hydrophobicity/hydrophilicity characteristics as the amino acid residue being substituted. Such amino acid characteristics are well known to those of skill in the art.
- the present invention further provides enhancer peptide sequences comprising amino acid sequences of FIGS.
- enhancer peptide sequences comprise one or more amino acid additions (generally no greater than about 15 amino acid residues in length) , deletions (for example, amino- or terminal- truncations) or non-conservative substitutions which nevertheless do not abolish the resulting enhancer peptide' s ability to increase the pharmacokinetic properties of core polypeptides to which they are linked relative to core polypeptides without such enhancer peptide sequences.
- Additions are generally no greater than about 15 amino acid residues and can include additions of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 consecutive amino acid residues.
- the total number of amino acid residues added to the original enhancer peptide is no greater than about 15 amino acid residues, more preferably no greater than about ten amino acid residues and most preferably no greater than about 5 amino acid residues.
- Deletions are preferably deletions of no greater than about 3 amino acid residues in total (either consecutive or non-consecutive residues) , more deletions preferably of 2 amino acids, most preferably deletions of single amino acids residues. Generally, deletions will be of amino acid residues corresponding to the "X" residues of the enhancer peptide consensus sequences.
- Enhancer peptide sequences of the invention also comprise the particular enhancer peptide sequences depicted in FIGS. 2, 13 and Table 1 exhibiting one, two or three non- conservative amino acid substitutions, with two such substitutions being preferred and one such substitution being most preferred.
- “Non conservative” substitutions refer to substitutions with amino acid residues of dissimilar charge, size, and/or hydrophobicity/ hydrophilicity characteristics from the amino acid residue being replaced. Such amino acid characteristics are well known to those of skill in the art.
- amino acid substitutions need not be, and in certain embodiments preferably are not, restricted to the genetically encoded amino acids.
- the peptides may contain genetically non-encoded amino acids.
- amino acid residues in the peptides may be substituted with naturally occurring non-encoded amino acids and synthetic amino acids.
- Certain commonly encountered amino acids which provide useful substitutions include, but are not limited to, ⁇ -alanine ( ⁇ -Ala) and other omega-amino acids such as 3-aminopropionic acid, 2, 3-diaminopropionic acid (Dpr) , 4-aminobutyric acid and so forth; -aminoisobutyric acid (Aib) ; e-aminohexanoic acid (Aha) ; ⁇ -aminovaleric acid (Ava) ; N-methylglycine or sarcosine (MeGly) ; ornithine (Orn) ; citrulline (Cit) ; t-butylalanine (t-BuA) ; t-butylglycine (t-BuG) ; N-methylisoleucine (Melle) ; phenylglycine (Phg) ; cyclohexylalanine (Cha) ; norleucine (Nle) ;
- the amino acids of the peptide will be substituted with L-enantiomeric amino acids, the substitutions are not limited to L-enantiomeric amino acids.
- substitutions are not limited to L-enantiomeric amino acids.
- mutated or altered forms are those situations where an L-amino acid is replaced with an identical D-amino acid (e.q. , L-Arg ⁇ D-Arg) or with a D-amino acid of the same category or subcategory (e.g. , L-Arg - D-Lys) , and vice versa.
- the present invention also contemplates peptide analogues wherein one or more amide linkage is optionally replaced with a linkage other than amide, preferably a substituted amide or an isostere of amide.
- amide linkage is optionally replaced with a linkage other than amide, preferably a substituted amide or an isostere of amide.
- amino acid residues within peptides are generally described in terms of amino acids, and preferred embodiments of the invention are exemplified by way of peptides, one having skill in the art will recognize that in embodiments having non-amide linkages, the term "amino acid” or “residue” as used herein refers to other bifunctional moieties bearing groups similar in structure to the side chains of the amino acids.
- amino acid residues may be blocked or unblocked.
- one or more amide linkages can be replaced with peptidomimetic or amide mimetic moieties which do not significantly interfere with the structure or activity of the peptides.
- Suitable amide mimetic moieties are described, for example, in Olson et al., 1993, J. Med. Chem. 36:3049.
- Enhancer peptide sequences can be used to enhance the pharmacokinetic properties of the core polypeptide as either N-terminal, C-terminal, or - and C-terminal additions. While it is preferable for the enhancer peptide sequences to be utilized in a pairwise fashion, that is, preferably hybrid polypeptides comprise an enhancer peptide sequence at both the amino- and carboxy-termini, hybrid polypeptides can also comprise a single enhancer peptide, said peptide present at either the amino- or carboxy- terminus of the hybrid polypeptide. Further, the enhancer peptides can be used in either forward or reverse orientation, or in any possible combination, linked to a core polypeptide.
- any of the enhancer peptides can be introduced at either the N-terminus or the C-terminus of the core polypeptide. Still further, multiple enhancer peptide sequences can be introduced to the N-, C-, or - and C-terminal positions of the hybrid polypeptides. Multiple enhancer peptide sequences can be linked directly one to another via the same sorts of linkages as used to link an enhancer peptide sequence to the core polypeptide (see below) . In addition, an intervening amino acid sequence of the same sort as described below can also be present between one or more of the multiple enhancer peptide sequences.
- enhancer peptide sequences will typically contain from 2 to about 10 individual enhancer peptide sequences (of the same or different amino acid sequence) , with about 2 to about 4 being preferred.
- the core polypeptide is generally linked to the enhancer peptides via a peptide amide linkage, although linkages other than amide linkages can be utilized to join the enhancer peptide sequences to the core polypeptides.
- linkages are well known to those of skill in the art and include, for example, any carbon-carbon, ester or chemical bond that functions to link the enhancer peptide sequences of the invention to a core peptide.
- an enhancer peptide sequence is linked directly to a core polypeptide.
- An enhancer peptide sequence can also be attached to an intervening amino acid sequence present between the enhancer peptide sequence and the core polypeptide.
- the intervening amino acid sequence can typically range in size from about 1 to about 50 amino acid residues in length, with about 1 to about 10 residues in length being preferred.
- the same sorts of linkages described for linking the enhancer peptide to the core polypeptide can be used to link the enhancer peptide to the intervening peptide.
- core and intervening amino acid sequences need not be restricted to the genetically encoded amino acids, but can comprise any of the amino acid and linkage modifications described above.
- the amino- and/or carboxy-termini of the resulting hybrid polypeptide can comprise an amino group (-NH 2 ) or a carboxy (-COOH) group, respectively.
- the hybrid polypeptide amino-terminus may, for example, represent a hydrophobic group, including but not limited to carbobenzyl, dansyl, t-butoxycarbonyl, decanoyl, napthoyl or other carbohydrate group; an acetyl group; 9- fluorenylmethoxy-carbonyl (FMOC) group; or a modified, non- naturally occurring amino acid residue.
- the hybrid polypeptide carboxy-terminus can, for example, represent an amido group; a t-butoxycarbonyl group; or a modified non-naturally occurring amino acid residue.
- the amino- and/or carboxy-termini of the resulting hybrid polypeptide can comprise any of the amino- and/or carboxy-terminal modifications depicted in the peptides shown in FIG. 13 or Table 2, below.
- a hybrid polypeptide comprises an amino acid sequence that is a non-naturally occurring amino acid sequence. That is, typically, the amino acid sequence of a hybrid polypeptide, does not consist solely of the amino acid sequence of a fragment of an endogenous, naturally occurring polypeptide. In addition, a hybrid polypeptide is not intended to consist solely of a full-length, naturally occurring polypeptide.
- Core polypeptides can comprise any polypeptide which may be introduced into a living system, for example, any polypeptide that can function as a pharmacologically useful polypeptide. Such core polypeptides can, for example, be useful for the treatment or prevention of disease, or for use in diagnostic or prognostic methods, including in vivo imaging methods.
- the lower size limit of a core polypeptide is typically about 4-6 amino acid residues.
- a core polypeptide ranges from about 4-6 amino acids to about 494-500 amino acids, with about 4 to about 94-100 amino acid residues being preferred and about 4 to about 34-40 amino acid residues being most preferred.
- Examples of possible core polypeptides include, but are not limited to, growth factors, cytokines, therapeutic polypeptides, hormones, e.q. , insulin, and peptide fragments of hormones, inhibitors or enhancers of cytokines, peptide growth and differentiation factors, interleukins, chemokines, interferons, colony stimulating factors, angiogenic factors, receptor ligands, agonists, antagonists or inverse agonists, peptide targeting agents such as imaging agents or cytotoxic targeting agents, and extracellular matrix proteins such as collagen, laminin, fibronectin and integrin to name a few.
- possible core polypeptides may include viral or bacterial polypeptides that may function either directly or indirectly as immunogens or antigens, and thus may be useful in the treatment or prevention of pathological disease.
- hybrid polypeptides which comprise core polypeptides derived from viral protein sequences are shown in FIG. 13, wherein the core polypeptide sequences are shaded.
- Core polypeptides also include, but are not limited to, the polypeptides disclosed in U.S. Patent No. 5,464,933, U.S. Patent No. 5,656,480 and WO 96/19495, each of which is incorporated herein by reference in its entirety.
- Core polypeptide sequences can further include, but are not limited to the polypeptide sequences depicted in Table 2, below. It is noted that the peptides listed in Table 2 include hybrid polypeptides in addition to core polypeptides. The sequence of the hybrid polypeptides will be apparent, however, in light of the terminal enhancer peptide sequences present as part of the hybrid polypeptides.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR9910626-4A BR9910626A (en) | 1998-05-20 | 1999-05-20 | Hybrid and core polypeptides, and process for enhancing the pharmacokinetic properties of a core polypeptide |
NZ508352A NZ508352A (en) | 1998-05-20 | 1999-05-20 | Hybrid polypeptides with a core therapeutic peptide further characterised with either amino and carboxy terminal linked enhancer or a carboxy terminal linked enhancer |
PL99344342A PL344342A1 (en) | 1998-05-20 | 1999-05-20 | Hybrid polypeptides with enhanced pharmacokinetic properties |
CA002332338A CA2332338A1 (en) | 1998-05-20 | 1999-05-20 | Hybrid polypeptides with enhanced pharmacokinetic properties |
MXPA00011314A MXPA00011314A (en) | 1998-05-20 | 1999-05-20 | Hybrid polypeptides with enhanced pharmacokinetic properties. |
IL13970299A IL139702A0 (en) | 1998-05-20 | 1999-05-20 | Hylbrid polypeptides with enhanced pharmacokinetic properties |
AU41949/99A AU766995C (en) | 1998-05-20 | 1999-05-20 | Hybrid polypeptides with enhanced pharmacokinetic properties |
JP2000549279A JP2002515449A (en) | 1998-05-20 | 1999-05-20 | Hybrid polypeptides with enhanced pharmacokinetic properties |
HU0101826A HUP0101826A3 (en) | 1998-05-20 | 1999-05-20 | Hybrid polypeptides with enhanced pharmacokinetic properties |
EP99925716A EP1079846A4 (en) | 1998-05-20 | 1999-05-20 | Hybrid polypeptides with enhanced pharmacokinetic properties |
IL139702A IL139702A (en) | 1998-05-20 | 2000-11-15 | Hybrid polypeptides with enhanced pharmacokinetic properties |
NO20005836A NO20005836L (en) | 1998-05-20 | 2000-11-17 | Hybrid polypeptides with enhanced pharmacokinetic properties |
HR20000789A HRP20000789A2 (en) | 1998-05-20 | 2000-11-17 | Hybrid polypeptides with enhanced pharmacokinetic properties |
HK02100923.0A HK1039747A1 (en) | 1998-05-20 | 2002-02-06 | Hybrid polypeptides with enhanced pharmacokinetic properties |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/082,279 US6258782B1 (en) | 1998-05-20 | 1998-05-20 | Hybrid polypeptides with enhanced pharmacokinetic properties |
US09/082,279 | 1998-05-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999059615A1 true WO1999059615A1 (en) | 1999-11-25 |
WO1999059615A9 WO1999059615A9 (en) | 2000-06-22 |
Family
ID=22170199
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/011219 WO1999059615A1 (en) | 1998-05-20 | 1999-05-20 | Hybrid polypeptides with enhanced pharmacokinetic properties |
Country Status (22)
Country | Link |
---|---|
US (3) | US6258782B1 (en) |
EP (1) | EP1079846A4 (en) |
JP (1) | JP2002515449A (en) |
KR (1) | KR100742789B1 (en) |
CN (1) | CN1205995C (en) |
AU (1) | AU766995C (en) |
BR (1) | BR9910626A (en) |
CA (1) | CA2332338A1 (en) |
HK (1) | HK1039747A1 (en) |
HR (1) | HRP20000789A2 (en) |
HU (1) | HUP0101826A3 (en) |
ID (1) | ID29141A (en) |
IL (2) | IL139702A0 (en) |
MX (1) | MXPA00011314A (en) |
NO (1) | NO20005836L (en) |
NZ (1) | NZ508352A (en) |
PL (1) | PL344342A1 (en) |
RU (1) | RU2236865C2 (en) |
TR (1) | TR200100163T2 (en) |
WO (1) | WO1999059615A1 (en) |
YU (1) | YU71800A (en) |
ZA (1) | ZA200006642B (en) |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001003723A1 (en) * | 1999-07-09 | 2001-01-18 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
US6258782B1 (en) | 1998-05-20 | 2001-07-10 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
US6277974B1 (en) | 1999-12-14 | 2001-08-21 | Cogent Neuroscience, Inc. | Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death |
WO2002096935A2 (en) * | 2001-05-31 | 2002-12-05 | Conjuchem, Inc. | Long lasting fusion peptide inhibitors for hiv infection |
US6528308B1 (en) | 2000-03-16 | 2003-03-04 | Duke University | Suppressor of HIV replication and transcription |
FR2832715A1 (en) * | 2001-11-29 | 2003-05-30 | Hippocampe | New peptide containing 25 - 40 amino acids and a sequence useful as therapeutic agents in the treatment of HIV virus infections |
WO2003066078A1 (en) * | 2002-02-07 | 2003-08-14 | Delta Biotechnology Limited | Hiv inhibiting proteins |
US6623741B1 (en) * | 2000-02-29 | 2003-09-23 | Trimeris, Inc. | Methods and compositions for inhibition of membrane fusion-associated events including RSV transmission |
EP1372686A2 (en) * | 1999-07-07 | 2004-01-02 | Trimeris Inc. | Methods and compositions for peptide synthesis |
EP1406573A2 (en) * | 2001-06-07 | 2004-04-14 | SkinMedica, Inc. | Conditioned cell culture media and uses thereof |
KR100447943B1 (en) * | 2000-11-06 | 2004-09-08 | 한국과학기술연구원 | Peptides for inhibition of HIV infection |
EP1479691A1 (en) * | 2001-05-31 | 2004-11-24 | ConjuChem, Inc. | Long lasting fusion peptide inhibitors for HIV infection |
US6858410B2 (en) | 2001-06-15 | 2005-02-22 | Hoffmann-La Roche Inc. | Process for making antifusogenic fusion peptides that form inclusion bodies |
EP1542718A2 (en) * | 2002-09-24 | 2005-06-22 | Dong Xie | Peptide derivative fusion inhibitors of hiv infection |
US7118746B1 (en) | 1999-05-14 | 2006-10-10 | Skinmedica, Inc. | Conditioned cell culture medium compositions and methods of use |
EP1708734A1 (en) * | 2004-01-07 | 2006-10-11 | Trimeris, Inc. | HIV gp41 HR2-DERIVED SYNTHETIC PEPTIDES, AND THEIR USE IN THERAPY TO INHIBIT TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS |
EP1747233A1 (en) * | 2004-05-06 | 2007-01-31 | ConjuChem Biotechnologies Inc. | Compounds for specific viral target |
EP1752469A2 (en) * | 2001-05-31 | 2007-02-14 | ConjuChem Biotechnologies Inc. | Long lasting fusion peptide inhibitors for HIV infection |
WO2008019817A1 (en) | 2006-08-17 | 2008-02-21 | F. Hoffmann-La Roche Ag | A conjugate of an antibody against ccr5 and an antifusogenic peptide |
WO2008110332A1 (en) | 2007-03-13 | 2008-09-18 | F.Hoffmann-La Roche Ag | Peptide-complement conjugates |
WO2009012944A1 (en) | 2007-07-20 | 2009-01-29 | F.Hoffmann-La Roche Ag | A conjugate of an antibody against cd4 and antifusogenic peptides |
US7744897B2 (en) | 2003-12-23 | 2010-06-29 | Dillon Susan B | Human immunodeficiency virus gp41 mimetibody polypeptides |
US7951920B2 (en) | 2006-08-17 | 2011-05-31 | Roche Palo Alto Llc | Conjugate of an antibody against CCR5 and an antifusogenic peptide |
US20120028887A1 (en) * | 2009-04-01 | 2012-02-02 | Yeda Research And Development Co. Ltd. | Lipopeptide inhibitors of hiv-1 |
WO2012035034A1 (en) | 2010-09-14 | 2012-03-22 | F. Hoffmann-La Roche Ag | Serpin-finger fusion polypeptide |
WO2013127288A1 (en) * | 2012-02-27 | 2013-09-06 | 中国人民解放军军事医学科学院毒物药物研究所 | Anti-hiv-1 polypeptide and use thereof |
US8603965B2 (en) | 2006-06-12 | 2013-12-10 | Fusogen Pharmaceuticals, Inc. | Pharmaceutical composition for the prophylaxis and treatment of HIV infection and its use |
WO2014041505A1 (en) * | 2012-09-13 | 2014-03-20 | Universite De Geneve | Cell penetrating peptides |
US11338027B2 (en) | 2016-09-21 | 2022-05-24 | Amal Therapeutics Sa | Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6261763B1 (en) * | 1995-06-07 | 2001-07-17 | Progenics Pharmaceuticals, Inc. | Fluorescence resonance energy transfer screening assay for the identification of compounds that are capable of abrogating macrophage-tropic HIV-1 cell fusion |
US7118859B2 (en) * | 1996-01-17 | 2006-10-10 | Progenics Pharmaceuticals, Inc. | Methods for inhibiting HIV-1 infection |
US7858298B1 (en) * | 1996-04-01 | 2010-12-28 | Progenics Pharmaceuticals Inc. | Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists |
US6344545B1 (en) * | 1996-06-14 | 2002-02-05 | Progenics Pharmaceuticals, Inc. | Method for preventing HIV-1 infection of CD4+ cells |
US20040086528A1 (en) * | 1996-06-14 | 2004-05-06 | Progenics Pharmaceuticals, Inc. | Uses of a chemokine receptor for inhibiting HIV-1 infection |
US20040228869A1 (en) * | 1998-12-16 | 2004-11-18 | Progenics Pharmaceuticals, Inc. | Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto |
US20080015348A1 (en) * | 1998-12-16 | 2008-01-17 | Progenics Pharmaceuticals, Inc. | Nucleic acids encoding polypeptides of anti-CCR5 antibodies |
CA2372338A1 (en) * | 1999-05-17 | 2000-11-23 | Conjuchem Inc. | Long lasting fusion peptide inhibitors of viral infection |
US7138119B2 (en) * | 2000-09-15 | 2006-11-21 | Progenics Pharmaceuticals, Inc. | Compositions and methods for inhibition of HIV-1 infection |
US7060273B2 (en) * | 2001-04-06 | 2006-06-13 | Progenics Pharmaceuticals, Inc. | Methods for inhibiting HIV-1 infection |
US20070031440A1 (en) * | 2001-08-30 | 2007-02-08 | Prior Christopher P | Modified transferin-antibody fusion proteins |
US8129504B2 (en) | 2001-08-30 | 2012-03-06 | Biorexis Technology, Inc. | Oral delivery of modified transferrin fusion proteins |
AU2002323501C1 (en) * | 2001-08-30 | 2010-04-29 | Biorexis Technology, Inc | Modified transferrin fusion proteins |
US20030226155A1 (en) * | 2001-08-30 | 2003-12-04 | Biorexis Pharmaceutical Corporation | Modified transferrin-antibody fusion proteins |
US7176278B2 (en) * | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
US20060241027A1 (en) * | 2002-02-07 | 2006-10-26 | Hans-Peter Hauser | Hiv inhibiting proteins |
DE60324664D1 (en) | 2002-02-22 | 2008-12-24 | Pdl Biopharma Inc | ANTI-CCR5 ANTIBODY |
US7122185B2 (en) * | 2002-02-22 | 2006-10-17 | Progenics Pharmaceuticals, Inc. | Anti-CCR5 antibody |
AU2003225710A1 (en) * | 2002-03-06 | 2003-09-22 | Arizona Board Of Regents | Composition and method for enhancing immune response |
NZ537493A (en) * | 2002-07-24 | 2007-05-31 | Hoffmann La Roche | Pegylated T1249 polypeptide |
US20060105387A1 (en) * | 2002-08-30 | 2006-05-18 | Prior Christopher P | Transferrin fusion proteins libraries |
JP4873860B2 (en) * | 2002-08-30 | 2012-02-08 | バイオレクシス ファーマシューティカル コーポレーション | Modified transferrin fusion protein |
US20040076637A1 (en) * | 2002-09-27 | 2004-04-22 | Delmedico Mary Kay | HIV-derived HR1 peptides modified to form stable trimers, and their use in therapy to inhibit transmission of human immunodeficiency virus |
US7556813B2 (en) * | 2002-09-27 | 2009-07-07 | Trimeris, Inc. | Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides |
US7045552B2 (en) * | 2002-09-27 | 2006-05-16 | Trimeris, Inc. | Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy |
US7420037B2 (en) * | 2003-02-13 | 2008-09-02 | Antigenics Inc. | Heat shock protein-based vaccines and immunotherapies |
US20070060512A1 (en) * | 2003-03-04 | 2007-03-15 | Homayoun Sadeghi | Dipeptidyl-peptidase protected protein |
ATE514718T1 (en) * | 2003-04-04 | 2011-07-15 | Univ Lausanne | PEPTABODY FOR CANCER TREATMENT |
DE60336978D1 (en) * | 2003-04-11 | 2011-06-16 | Pasteur Institut | Synthetic peptide HIV vaccine: the CBD epitope as an efficient immunogen for the induction of HIV-neutralizing antibodies |
US7309491B2 (en) * | 2003-04-11 | 2007-12-18 | Antigenics Inc. | Heat shock protein-based vaccines and immunotherapies |
US7379700B2 (en) * | 2003-05-06 | 2008-05-27 | Canon Kabushiki Kaisha | Image reading apparatus with rotatable internal and external guides |
WO2004106364A1 (en) * | 2003-08-05 | 2004-12-09 | Cornell Research Foundation, Inc. | Stabilizing peptides and their use in the preparation of stabilized hiv inhibitors |
EP1663278A4 (en) * | 2003-08-28 | 2009-07-29 | Biorexis Pharmaceutical Corp | Epo mimetic peptides and fusion proteins |
US20060205037A1 (en) * | 2003-08-28 | 2006-09-14 | Homayoun Sadeghi | Modified transferrin fusion proteins |
DE602005016658D1 (en) * | 2004-04-08 | 2009-10-29 | Jadolabs Gmbh | PENETRATED CONJUGATES WITH A STRUCTURE INTERACTING WITH CELL MEMBERS RAFTS AND ITS USE |
GB0422439D0 (en) * | 2004-10-08 | 2004-11-10 | European Molecular Biology Lab Embl | Inhibitors of infection |
US20070041943A1 (en) * | 2004-12-29 | 2007-02-22 | Children's Hospital Research | Expression of virus entry inhibitors and recombinant AAV thereof |
AU2006272750B2 (en) * | 2005-07-22 | 2011-09-29 | Cytodyn, Inc. | Methods for reducing viral load in HIV-1-infected patients |
TW200722436A (en) * | 2005-10-21 | 2007-06-16 | Hoffmann La Roche | A peptide-immunoglobulin-conjugate |
WO2007097903A2 (en) * | 2006-02-02 | 2007-08-30 | Trimeris, Inc. | Hiv fusion inhibitor peptides with improved biological properties |
US7682619B2 (en) | 2006-04-06 | 2010-03-23 | Cornell Research Foundation, Inc. | Canine influenza virus |
AU2007278994B2 (en) | 2006-07-24 | 2013-08-15 | Biorexis Pharmaceutical Corporation | Exendin fusion proteins |
JP5492563B2 (en) | 2006-12-12 | 2014-05-14 | バイオレクシス ファーマシューティカル コーポレーション | Transferrin fusion protein library |
US20090088378A1 (en) * | 2007-01-12 | 2009-04-02 | Omar Quraishi | Long lasting inhibitors of viral infection |
WO2008124013A1 (en) * | 2007-04-03 | 2008-10-16 | Trimeris, Inc. | Novel formulations for delivery of antiviral peptide therapeutics |
JP2010527376A (en) * | 2007-05-16 | 2010-08-12 | コンジュケム バイオテクノロジーズ インコーポレイテッド | Cysteinic acid derivatives of antiviral peptides |
US20090074766A1 (en) * | 2007-09-14 | 2009-03-19 | Ketas Thomas J | Methods of inhibiting HIV-2 infection |
MX2010003179A (en) * | 2007-09-25 | 2010-04-30 | Trimeris Inc | Methods of synthesis for therapeuthic anti-hiv peptides. |
CN102448982B (en) * | 2009-03-31 | 2018-04-20 | 华盛顿大学 | For adjusting the active composition and method of Complement Regulatory Protein on target cell |
CA2797033C (en) | 2010-04-22 | 2021-10-19 | Longevity Biotech, Inc. | Highly active polypeptides and methods of making and using the same |
WO2013096939A1 (en) * | 2011-12-23 | 2013-06-27 | Sri International | Selective binding compounds |
EP2834264A1 (en) | 2012-04-04 | 2015-02-11 | Yeda Research and Development Co. Ltd. | Lipopeptide conjugates comprising sphingolipid and hiv gp41 derived peptides |
WO2014145718A2 (en) | 2013-03-15 | 2014-09-18 | Longevity Biotech, Inc. | Peptides comprising non-natural amino acids and methods of making and using the same |
CN105646717B (en) * | 2016-01-26 | 2020-06-09 | 复旦大学 | Long-acting HIV fusion inhibitor and application thereof |
EP3214093A1 (en) * | 2016-03-03 | 2017-09-06 | Fondation The Ark | Fusion respiratory syncytial virus inhibitors and use thereof |
CN106279373B (en) * | 2016-08-17 | 2020-01-24 | 广州宏柯源生物科技有限公司 | Polypeptide foaming agent, preparation method and application thereof |
AU2018326439A1 (en) * | 2017-08-29 | 2020-04-16 | Pharis Biotec Gmbh | Protransduzin-D - improved enhancer of gene transfer |
CN110357968B (en) * | 2018-04-08 | 2023-08-25 | 吉林省汇融生物科技有限公司 | Anti-tumor fusion protein and preparation method and application thereof |
CN116162136A (en) * | 2021-11-24 | 2023-05-26 | 成都奥达生物科技有限公司 | Anti-syncytial virus membrane fusion inhibitor |
CN117186187A (en) * | 2023-07-12 | 2023-12-08 | 中国医学科学院病原生物学研究所 | Anti-respiratory syncytial virus membrane fusion inhibitor and pharmaceutical application thereof |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0272858A2 (en) * | 1986-12-15 | 1988-06-29 | Repligen Corporation | Recombinant HIV envelope proteins produced in insect cells |
EP0306912A2 (en) * | 1987-09-08 | 1989-03-15 | Albany Medical College | Immunogenic composites capable of selectively inducing antibody production and pharmaceutical compositions employing the same. |
WO1991007664A1 (en) * | 1989-11-13 | 1991-05-30 | Cambridge Biotech Corporation | Diagnostic proteins to test for more than one antibody |
WO1991009872A2 (en) * | 1989-12-13 | 1991-07-11 | Univax Biolog Inc | Hiv-1 env fragment fusion protein |
WO1993014207A1 (en) * | 1992-01-06 | 1993-07-22 | Connaught Laboratories Limited | Chimeric immunogens |
EP0578293A1 (en) * | 1992-06-18 | 1994-01-12 | Akzo Nobel N.V. | E-coli P-fimbrine as immunogenic carrier system against GnRH |
US5723129A (en) * | 1991-10-16 | 1998-03-03 | University Of Saskatchewan | GnRH-leukotoxin chimeras |
US5763160A (en) * | 1988-02-12 | 1998-06-09 | United Biomedical, Inc. | Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines |
US5843913A (en) * | 1995-06-07 | 1998-12-01 | Connaught Laboratories Limited | Nucleic acid respiratory syncytial virus vaccines |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5357041A (en) * | 1991-12-06 | 1994-10-18 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Heparin- and sulfatide-binding peptides from the type I repeats of human thrombospondin |
DE69326069T2 (en) | 1992-07-20 | 2000-03-23 | Univ Durham | COMPOSITIONS THAT INHIBIT HIV REPLICATION |
EP0673387B1 (en) * | 1992-12-11 | 1999-09-22 | University Of Florida | Materials and methods for control of pests |
US5464934A (en) | 1993-05-14 | 1995-11-07 | Mallinckrodt Medical, Inc. | Metal chelates as spacer compounds in biologically active peptides |
US6479055B1 (en) | 1993-06-07 | 2002-11-12 | Trimeris, Inc. | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission |
US5464933A (en) | 1993-06-07 | 1995-11-07 | Duke University | Synthetic peptide inhibitors of HIV transmission |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
FR2739621B1 (en) * | 1995-10-05 | 1997-12-05 | Centre Nat Rech Scient | PEPTIDES FOR USE AS VECTORS FOR INTRACELLULAR ADDRESSING OF ACTIVE MOLECULES |
US6258782B1 (en) * | 1998-05-20 | 2001-07-10 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
-
1998
- 1998-05-20 US US09/082,279 patent/US6258782B1/en not_active Expired - Fee Related
-
1999
- 1999-05-20 YU YU71800A patent/YU71800A/en unknown
- 1999-05-20 JP JP2000549279A patent/JP2002515449A/en active Pending
- 1999-05-20 NZ NZ508352A patent/NZ508352A/en unknown
- 1999-05-20 AU AU41949/99A patent/AU766995C/en not_active Ceased
- 1999-05-20 HU HU0101826A patent/HUP0101826A3/en unknown
- 1999-05-20 CA CA002332338A patent/CA2332338A1/en not_active Abandoned
- 1999-05-20 US US09/315,304 patent/US6348568B1/en not_active Expired - Fee Related
- 1999-05-20 EP EP99925716A patent/EP1079846A4/en not_active Withdrawn
- 1999-05-20 MX MXPA00011314A patent/MXPA00011314A/en not_active IP Right Cessation
- 1999-05-20 CN CNB998089362A patent/CN1205995C/en not_active Expired - Fee Related
- 1999-05-20 RU RU2000132227/15A patent/RU2236865C2/en not_active IP Right Cessation
- 1999-05-20 IL IL13970299A patent/IL139702A0/en active IP Right Grant
- 1999-05-20 ID IDW20002674A patent/ID29141A/en unknown
- 1999-05-20 WO PCT/US1999/011219 patent/WO1999059615A1/en not_active Application Discontinuation
- 1999-05-20 TR TR2001/00163T patent/TR200100163T2/en unknown
- 1999-05-20 BR BR9910626-4A patent/BR9910626A/en not_active Application Discontinuation
- 1999-05-20 PL PL99344342A patent/PL344342A1/en not_active Application Discontinuation
- 1999-05-20 KR KR1020007012887A patent/KR100742789B1/en not_active IP Right Cessation
-
2000
- 2000-11-15 IL IL139702A patent/IL139702A/en not_active IP Right Cessation
- 2000-11-15 ZA ZA200006642A patent/ZA200006642B/en unknown
- 2000-11-17 HR HR20000789A patent/HRP20000789A2/en not_active Application Discontinuation
- 2000-11-17 NO NO20005836A patent/NO20005836L/en not_active Application Discontinuation
-
2001
- 2001-04-13 US US09/834,784 patent/US6562787B1/en not_active Expired - Fee Related
-
2002
- 2002-02-06 HK HK02100923.0A patent/HK1039747A1/en unknown
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0272858A2 (en) * | 1986-12-15 | 1988-06-29 | Repligen Corporation | Recombinant HIV envelope proteins produced in insect cells |
EP0306912A2 (en) * | 1987-09-08 | 1989-03-15 | Albany Medical College | Immunogenic composites capable of selectively inducing antibody production and pharmaceutical compositions employing the same. |
US5763160A (en) * | 1988-02-12 | 1998-06-09 | United Biomedical, Inc. | Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines |
WO1991007664A1 (en) * | 1989-11-13 | 1991-05-30 | Cambridge Biotech Corporation | Diagnostic proteins to test for more than one antibody |
WO1991009872A2 (en) * | 1989-12-13 | 1991-07-11 | Univax Biolog Inc | Hiv-1 env fragment fusion protein |
US5723129A (en) * | 1991-10-16 | 1998-03-03 | University Of Saskatchewan | GnRH-leukotoxin chimeras |
WO1993014207A1 (en) * | 1992-01-06 | 1993-07-22 | Connaught Laboratories Limited | Chimeric immunogens |
EP0578293A1 (en) * | 1992-06-18 | 1994-01-12 | Akzo Nobel N.V. | E-coli P-fimbrine as immunogenic carrier system against GnRH |
US5843913A (en) * | 1995-06-07 | 1998-12-01 | Connaught Laboratories Limited | Nucleic acid respiratory syncytial virus vaccines |
Non-Patent Citations (1)
Title |
---|
See also references of EP1079846A4 * |
Cited By (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6562787B1 (en) | 1998-05-20 | 2003-05-13 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
US6258782B1 (en) | 1998-05-20 | 2001-07-10 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
US6656906B1 (en) | 1998-05-20 | 2003-12-02 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
US6348568B1 (en) | 1998-05-20 | 2002-02-19 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
US7297784B2 (en) | 1998-05-20 | 2007-11-20 | Trimeris, Inc. | DNA encoding T-1249 and other viral fusion inhibitor peptides useful for treating aids |
US9458486B2 (en) | 1999-05-14 | 2016-10-04 | Allergen, Inc. | Conditioned cell culture medium compositions and methods of use |
US8476231B2 (en) | 1999-05-14 | 2013-07-02 | Allergan, Inc. | Conditioned cell culture medium compositions and methods of use |
US8138147B2 (en) | 1999-05-14 | 2012-03-20 | Skinmedica, Inc. | Conditioned cell culture medium compositions and methods of use |
US8361485B2 (en) | 1999-05-14 | 2013-01-29 | Skinmedica, Inc. | Conditioned cell culture medium compositions and methods of use |
US7118746B1 (en) | 1999-05-14 | 2006-10-10 | Skinmedica, Inc. | Conditioned cell culture medium compositions and methods of use |
US6767993B2 (en) | 1999-07-07 | 2004-07-27 | Brian Bray | Methods and compositions for peptide synthesis |
EP1372686A2 (en) * | 1999-07-07 | 2004-01-02 | Trimeris Inc. | Methods and compositions for peptide synthesis |
EP1372686A4 (en) * | 1999-07-07 | 2004-01-02 | Trimeris Inc | Methods and compositions for peptide synthesis |
WO2001003723A1 (en) * | 1999-07-09 | 2001-01-18 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
US6277974B1 (en) | 1999-12-14 | 2001-08-21 | Cogent Neuroscience, Inc. | Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death |
US6623741B1 (en) * | 2000-02-29 | 2003-09-23 | Trimeris, Inc. | Methods and compositions for inhibition of membrane fusion-associated events including RSV transmission |
US7037645B2 (en) | 2000-03-16 | 2006-05-02 | Duke University | Methods for identification of CDS8+ suppressor molecules |
US6528308B1 (en) | 2000-03-16 | 2003-03-04 | Duke University | Suppressor of HIV replication and transcription |
KR100447943B1 (en) * | 2000-11-06 | 2004-09-08 | 한국과학기술연구원 | Peptides for inhibition of HIV infection |
EP1752469A3 (en) * | 2001-05-31 | 2007-03-21 | ConjuChem Biotechnologies Inc. | Long lasting fusion peptide inhibitors for HIV infection |
WO2002096935A2 (en) * | 2001-05-31 | 2002-12-05 | Conjuchem, Inc. | Long lasting fusion peptide inhibitors for hiv infection |
US7741453B2 (en) | 2001-05-31 | 2010-06-22 | Conjuchem Biotechnologies, Inc. | Long lasting fusion peptide inhibitors for HIV infection |
EP1479691A1 (en) * | 2001-05-31 | 2004-11-24 | ConjuChem, Inc. | Long lasting fusion peptide inhibitors for HIV infection |
EP1752469A2 (en) * | 2001-05-31 | 2007-02-14 | ConjuChem Biotechnologies Inc. | Long lasting fusion peptide inhibitors for HIV infection |
WO2002096935A3 (en) * | 2001-05-31 | 2003-10-02 | Conjuchem Inc | Long lasting fusion peptide inhibitors for hiv infection |
EP1406573A4 (en) * | 2001-06-07 | 2005-03-30 | Skinmedica Inc | Conditioned cell culture media and uses thereof |
EP1406573A2 (en) * | 2001-06-07 | 2004-04-14 | SkinMedica, Inc. | Conditioned cell culture media and uses thereof |
US6858410B2 (en) | 2001-06-15 | 2005-02-22 | Hoffmann-La Roche Inc. | Process for making antifusogenic fusion peptides that form inclusion bodies |
US7348423B2 (en) | 2001-06-15 | 2008-03-25 | Hoffmann-La Roche Inc. | Nucleic acids encoding fusion peptides |
FR2832715A1 (en) * | 2001-11-29 | 2003-05-30 | Hippocampe | New peptide containing 25 - 40 amino acids and a sequence useful as therapeutic agents in the treatment of HIV virus infections |
WO2003066078A1 (en) * | 2002-02-07 | 2003-08-14 | Delta Biotechnology Limited | Hiv inhibiting proteins |
US8470527B2 (en) | 2002-09-24 | 2013-06-25 | Frontier Biotechnologies, Co., Ltd. | Method of inhibiting HIV-1 replication by administering modified GP41 C34 peptide derivatives with enhanced pharmacological properties |
EP1542718A2 (en) * | 2002-09-24 | 2005-06-22 | Dong Xie | Peptide derivative fusion inhibitors of hiv infection |
US7575750B2 (en) * | 2002-09-24 | 2009-08-18 | Frontiers Biotechnologies Col, Ltd. | Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity |
EP1542718A4 (en) * | 2002-09-24 | 2011-04-06 | Dong Xie | Peptide derivative fusion inhibitors of hiv infection |
US7744897B2 (en) | 2003-12-23 | 2010-06-29 | Dillon Susan B | Human immunodeficiency virus gp41 mimetibody polypeptides |
EP1708734A4 (en) * | 2004-01-07 | 2009-06-17 | Trimeris Inc | HIV gp41 HR2-DERIVED SYNTHETIC PEPTIDES, AND THEIR USE IN THERAPY TO INHIBIT TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS |
EP1708734A1 (en) * | 2004-01-07 | 2006-10-11 | Trimeris, Inc. | HIV gp41 HR2-DERIVED SYNTHETIC PEPTIDES, AND THEIR USE IN THERAPY TO INHIBIT TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS |
EP1747233A4 (en) * | 2004-05-06 | 2007-04-25 | Compounds for specific viral target | |
EP1747233A1 (en) * | 2004-05-06 | 2007-01-31 | ConjuChem Biotechnologies Inc. | Compounds for specific viral target |
US8603965B2 (en) | 2006-06-12 | 2013-12-10 | Fusogen Pharmaceuticals, Inc. | Pharmaceutical composition for the prophylaxis and treatment of HIV infection and its use |
US7951920B2 (en) | 2006-08-17 | 2011-05-31 | Roche Palo Alto Llc | Conjugate of an antibody against CCR5 and an antifusogenic peptide |
WO2008019817A1 (en) | 2006-08-17 | 2008-02-21 | F. Hoffmann-La Roche Ag | A conjugate of an antibody against ccr5 and an antifusogenic peptide |
WO2008110332A1 (en) | 2007-03-13 | 2008-09-18 | F.Hoffmann-La Roche Ag | Peptide-complement conjugates |
WO2009012944A1 (en) | 2007-07-20 | 2009-01-29 | F.Hoffmann-La Roche Ag | A conjugate of an antibody against cd4 and antifusogenic peptides |
EP2526972A1 (en) | 2007-07-20 | 2012-11-28 | F. Hoffmann-La Roche AG | A conjugate of an antibody against CD4 and antifusogenic peptides |
US20120028887A1 (en) * | 2009-04-01 | 2012-02-02 | Yeda Research And Development Co. Ltd. | Lipopeptide inhibitors of hiv-1 |
US9403896B2 (en) | 2010-09-14 | 2016-08-02 | Hoffmann-La Roche Inc. | Serpin-finger fusion polypeptide |
WO2012035034A1 (en) | 2010-09-14 | 2012-03-22 | F. Hoffmann-La Roche Ag | Serpin-finger fusion polypeptide |
WO2013127288A1 (en) * | 2012-02-27 | 2013-09-06 | 中国人民解放军军事医学科学院毒物药物研究所 | Anti-hiv-1 polypeptide and use thereof |
WO2014041505A1 (en) * | 2012-09-13 | 2014-03-20 | Universite De Geneve | Cell penetrating peptides |
US9657064B2 (en) | 2012-09-13 | 2017-05-23 | Les Hopitaux Universitaires De Geneve | Cell penetrating peptides |
AU2013316679B2 (en) * | 2012-09-13 | 2017-12-14 | Les Hopitaux Universitaires De Geneve | Cell penetrating peptides |
RU2670488C2 (en) * | 2012-09-13 | 2018-10-23 | Юниверсите Де Женев | Novel cell-penetrating peptides |
EP2895499B1 (en) * | 2012-09-13 | 2019-04-10 | Université de Genève | Cell penetrating peptides |
US11338027B2 (en) | 2016-09-21 | 2022-05-24 | Amal Therapeutics Sa | Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer |
Also Published As
Publication number | Publication date |
---|---|
TR200100163T2 (en) | 2001-06-21 |
HUP0101826A3 (en) | 2005-12-28 |
MXPA00011314A (en) | 2003-04-22 |
ID29141A (en) | 2001-08-02 |
RU2236865C2 (en) | 2004-09-27 |
NZ508352A (en) | 2004-02-27 |
AU4194999A (en) | 1999-12-06 |
ZA200006642B (en) | 2001-05-28 |
NO20005836D0 (en) | 2000-11-17 |
PL344342A1 (en) | 2001-11-05 |
HK1039747A1 (en) | 2002-06-21 |
CN1205995C (en) | 2005-06-15 |
BR9910626A (en) | 2006-01-03 |
US6562787B1 (en) | 2003-05-13 |
US6258782B1 (en) | 2001-07-10 |
JP2002515449A (en) | 2002-05-28 |
IL139702A0 (en) | 2002-02-10 |
HUP0101826A2 (en) | 2001-09-28 |
AU766995C (en) | 2004-12-02 |
KR100742789B1 (en) | 2007-07-25 |
KR20010043681A (en) | 2001-05-25 |
CA2332338A1 (en) | 1999-11-25 |
EP1079846A4 (en) | 2003-01-02 |
HRP20000789A2 (en) | 2001-06-30 |
CN1310626A (en) | 2001-08-29 |
YU71800A (en) | 2004-05-12 |
IL139702A (en) | 2007-10-31 |
AU766995B2 (en) | 2003-10-30 |
US6348568B1 (en) | 2002-02-19 |
WO1999059615A9 (en) | 2000-06-22 |
NO20005836L (en) | 2001-01-19 |
EP1079846A1 (en) | 2001-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU766995C (en) | Hybrid polypeptides with enhanced pharmacokinetic properties | |
US7297784B2 (en) | DNA encoding T-1249 and other viral fusion inhibitor peptides useful for treating aids | |
EP0652895B1 (en) | Compounds which inhibit hiv replication | |
US8034899B2 (en) | HIV fusion inhibitor peptides with improved biological properties | |
CZ20004324A3 (en) | Hybrid polypeptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: P-718/00 Country of ref document: YU Ref document number: 99808936.2 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 7-13, DESCRIPTION, REPLACED BY NEW PAGES 7-13; PAGES 21-49, CLAIMS, REPLACED BY NEW PAGES 21-49; PAGES 1/23-23/23, DRAWINGS, REPLACED BY NEW PAGES 1/29-29/29; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
ENP | Entry into the national phase |
Ref document number: 2332338 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000/06642 Country of ref document: ZA Ref document number: 139702 Country of ref document: IL Ref document number: 200006642 Country of ref document: ZA Ref document number: 41949/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: P20000789A Country of ref document: HR Ref document number: 1020007012887 Country of ref document: KR Ref document number: PA/a/2000/011314 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2000 549279 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2000-4324 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 508352 Country of ref document: NZ Ref document number: 1999925716 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2000/836/CHE Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001/00163 Country of ref document: TR |
|
WWP | Wipo information: published in national office |
Ref document number: 1999925716 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007012887 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: PV2000-4324 Country of ref document: CZ |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 7-13 AND 21-49, DESCRIPTION, REPLACED BY NEW PAGES 7-13 AND 21-49; PAGES 1/29-29/29, DRAWINGS, REPLACED BY NEW PAGES 1/29-29/29; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
WWG | Wipo information: grant in national office |
Ref document number: 41949/99 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: PI9910626 Country of ref document: BR |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020007012887 Country of ref document: KR |